Hemostemix (CVE:HEM) Shares Down 11.1% – Time to Sell?
by Tristan Rich · The Markets DailyHemostemix Inc. (CVE:HEM – Get Free Report)’s share price dropped 11.1% on Monday . The stock traded as low as C$0.08 and last traded at C$0.08. Approximately 155,328 shares changed hands during mid-day trading, an increase of 70% from the average daily volume of 91,372 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Down 5.6%
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a 50 day moving average price of C$0.09 and a 200-day moving average price of C$0.10. The firm has a market cap of C$16.02 million, a price-to-earnings ratio of -3.15 and a beta of 1.25.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.